Joerger, M.
~ 300  results:
Search for persons X
?
 
?
2

146P A novel allosteric oral immunotherapy small molecule m..:

Pejoski, D. ; Suess, C. ; Gouiller, A....
Immuno-Oncology and Technology.  20 (2023)  - p. 100618 , 2023
 
?
 
?
 
?
7

200MO Anti–IL-8 BMS-986253 + nivolumab (NIVO) ± ipilimumab ..:

Simonelli, M. ; Calvo, E. ; Davar, D....
Immuno-Oncology and Technology.  16 (2022)  - p. 100311 , 2022
 
?
 
?
10

Continuous vs intermittent adenosine 2A receptor (A2AR) inh..:

Lin, C.C. ; Joerger, M. ; Grell, P....
European Journal of Cancer.  138 (2020)  - p. S12-S13 , 2020
 
?
11

OFF‐LABEL USE IN LYMPHOMA PATIENTS IN SWITZERLAND:

Herbrand, A.K. ; Schmitt, A.M. ; Joerger, M...
Hematological Oncology.  37 (2019)  S2 - p. 537-538 , 2019
 
?
12

Phase I trial of the oral smoothened inhibitor sonidegib in..:

Stathis, A. ; Hess, D. ; von Moos, R....
Investigational New Drugs.  35 (2017)  6 - p. 766-772 , 2017
 
?
13

Novel Genetic Variants in Carboxylesterase 1 Predict Severe..:

Hamzic, S ; Kummer, D ; Milesi, S...
Clinical Pharmacology & Therapeutics.  102 (2017)  5 - p. 796-804 , 2017
 
?
14

Pharmacogenetic variants associated with outcome in patient..:

Meulendijks, D ; Rozeman, E A ; Cats, A...
The Pharmacogenomics Journal.  17 (2016)  5 - p. 441-451 , 2016
 
?
15

The impact of ABCC11 polymorphisms on the risk of early-ons..:

Hamzic, S ; Wenger, N ; Froehlich, T K...
The Pharmacogenomics Journal.  17 (2016)  4 - p. 319-324 , 2016
 
1-15